, a distinct segment specialty pharmaceutical company, today reported financial outcomes for the second quarter of 2011. The Company also separately announced that it offers entered into an agreement to acquire a minority ownership in Westborough, MA, centered Aciex Therapeutics Inc., an ophthalmic drug development business with a focus on developing novel therapeutics to treat front-of-eye diseases. Aciex’s pipeline includes three clinical stage assets and four pre-IND stage assets. Furthermore, Akorn signed a global licensing and manufacturing contract for just one of Aciex’s business lead products. Second Quarter Highlights Revenue development of 59 percent over the comparable prior year one fourth, or 41 percent excluding the impact of AVR. Eighth consecutive quarter of core income and adjusted EBITDA development.Related StoriesFDA grants accelerated approval for Tagrisso to take care of patients with advanced NSCLCNew findings reveal association between colorectal cancer and melanoma drug treatmentUnderstanding how schizophrenia affects workings of the brainA nab-paclitaxel and bevacizumab combination therapy also increased anti-tumor activity in fresh models of inflammatory breast cancer . Provided the same dosing regimen, mixture treatment inhibited tumor growth in mice by 96 percent and led to 22 percent full responses.
Akorn second quarter revenue grows 59 percent to $32.
Warning: Division by zero in /home/amandabrayman/public_html/wp-includes/comment-template.php on line 1379